Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511224 | 0.71 | CYP2C19 (0.35) | CTSKFDPSSLC6A3SMN1; SMN2 | |
| SCHEMBL20995405 | 0.71 | FDPS (0.41) | CTSKFDPSSLC6A3HRH2HRH1 | |
| SCHEMBL12854076 | 0.71 | FDPS (0.36) | FDPSSLC6A3 | |
| SCHEMBL21186361 | 0.70 | FDPS (0.41) | CTSKFDPSSLC6A3HRH2HRH1 | |
| SCHEMBL17504097 | 0.70 | CTSK (0.34) | CTSKFDPSSLC6A3HRH2HRH1 | |
| SCHEMBL3309122 | 0.69 | PLA2G4A (0.43) | FDPSHRH2HRH1L3MBTL1TLR7 | |
| SCHEMBL4584005 | 0.69 | PLA2G4A (0.43) | FDPSHRH2HRH1L3MBTL1TLR7 | |
| SCHEMBL4584723 | 0.69 | PLA2G4A (0.43) | FDPSHRH2HRH1L3MBTL1TLR7 | |
| SCHEMBL10577019 | 0.69 | PLA2G4A (0.43) | FDPSHRH2HRH1L3MBTL1TLR7 | |
| SCHEMBL4584899 | 0.69 | PLA2G4A (0.43) | FDPSHRH2HRH1L3MBTL1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2985279-B1 | Heterocyclic compounds with working memory enhancing activity | RED BULL GMBH (AT) | 2017-08-02 | — | — | EP | claimed |
| US-20170174642-A1 | HETEROCYCLIC COMPOUNDS WITH WORKING MEMORY ENHANCING ACTIVITY | COGMOTIV FLEXCO (AT) | 2017-06-22 | — | — | US | claimed |
| WO-2016023997-A1 | HETEROCYCLIC COMPOUNDS WITH WORKING MEMORY ENHANCING ACTIVITY | RED BULL GMBH (AT) | 2016-02-18 | — | — | WO | claimed |
| EP-2985279-A1 | Heterocyclic compounds with working memory enhancing activity | Red Bull GmbH (AT) | 2016-02-17 | — | — | EP | claimed |
| US-10221147-B2 | Heterocyclic compounds with working memory enhancing activity | RED BULL GMBH (AT) | 2019-03-05 | — | — | US | disclosed |
| EP-2985279-B1 | Heterocyclic compounds with working memory enhancing activity | RED BULL GMBH (AT) | 2017-08-02 | — | — | EP | disclosed |
| US-20170174642-A1 | HETEROCYCLIC COMPOUNDS WITH WORKING MEMORY ENHANCING ACTIVITY | COGMOTIV FLEXCO (AT) | 2017-06-22 | — | — | US | disclosed |
| WO-2016023997-A1 | HETEROCYCLIC COMPOUNDS WITH WORKING MEMORY ENHANCING ACTIVITY | RED BULL GMBH (AT) | 2016-02-18 | — | — | WO | disclosed |
| EP-2985279-A1 | Heterocyclic compounds with working memory enhancing activity | Red Bull GmbH (AT) | 2016-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174642-A1 | HETEROCYCLIC COMPOUNDS WITH WORKING MEMORY ENHANCING ACTIVITY | TAAR1, ACHE, RIF1 | CTSK 3343/4885FDPS 2877/4885SLC6A3 683/4885 |
| US-10221147-B2 | Heterocyclic compounds with working memory enhancing activity | TAAR1, ACHE, RIF1 | CTSK 3343/4885FDPS 2877/4885SLC6A3 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.